Literature DB >> 30910406

Systematic review of health economic evaluation studies of dengue vaccines.

Patrícia Coelho de Soárez1, Aline Blumer Silva2, Bruno Azevedo Randi3, Laura Marques Azevedo2, Hillegonda Maria Dutilh Novaes2, Ana Marli Christovam Sartori3.   

Abstract

OBJECTIVES: To review the literature on economic evaluation of dengue vaccination to produce evidence to support a local cost-effectiveness study and to subsidize the decision to introduce a dengue vaccine in the Brazilian National Immunization Program.
METHODS: We systematically searched multiple databases (MEDLINE (via PubMed), EMBASE, SCOPUS, NHS Economic Evaluation Database (NHS EED), HTA Database (via Centre for Reviews and Dissemination - CRD) and LILACS), selecting full HEEs of dengue vaccine. Two independent reviewers screened articles for relevance and extracted the data. The methodology for the quality reporting was assessed using CHEERS checklist. We performed a qualitative narrative synthesis.
RESULTS: Thirteen studies conducted in Asian and Latin America countries were reviewed. All studies were favorable to the incorporation of the vaccine. However, the assumptions and values assumed for vaccine efficacy, safety and duration of protection, as well as the choice of the study population and the type of model used in the analyses, associated to an insufficient reporting of the methodological steps, affect the validity of the studies' results. The quality reporting appraisal showed that the majority (8/13) of the studies reported less than 55% of the CHEERS checklists' items.
CONCLUSIONS: This systematic review shows that the economic evaluation of dengue vaccination did not adhere to key recommended general methods for economic evaluation. The presented cost-effectiveness results should not be transferred to other countries. It is recommended to conduct studies with local epidemiological and cost data, as well as assumptions about vaccination that reflect the results observed in clinical trials.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cost-benefit analysis; Cost-effectiveness analysis; Cost-utility analysis; Dengue vaccines

Year:  2019        PMID: 30910406     DOI: 10.1016/j.vaccine.2019.03.026

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Why should we apply ABM for decision analysis for infectious diseases?-An example for dengue interventions.

Authors:  Florian Miksch; Beate Jahn; Kurt Junshean Espinosa; Jagpreet Chhatwal; Uwe Siebert; Nikolas Popper
Journal:  PLoS One       Date:  2019-08-27       Impact factor: 3.240

Review 2.  Cost-utility analysis in chronic kidney disease patients undergoing kidney transplant; what pays? A systematic review.

Authors:  Sameera Senanayake; Nicholas Graves; Helen Healy; Keshwar Baboolal; Sanjeewa Kularatna
Journal:  Cost Eff Resour Alloc       Date:  2020-05-19

3.  The cost-effectiveness of controlling dengue in Indonesia using wMel Wolbachia released at scale: a modelling study.

Authors:  Oliver J Brady; Dinar D Kharisma; Nandyan N Wilastonegoro; Kathleen M O'Reilly; Emilie Hendrickx; Leonardo S Bastos; Laith Yakob; Donald S Shepard
Journal:  BMC Med       Date:  2020-07-09       Impact factor: 8.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.